Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Their first launch was ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease.

Morgan Prestwich have been, and currently still are, retained by Kiniksa to build their European and some of their senior US operations:

European:
- Clinical
- Supply Chain
- Pharmacovigilance
- Quality
- Regulatory

US:
- VP Market Access
- VP Clinical Operations
- Director Supply Chain
- VP Medical Affairs
- Director Clinical Operations